Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interfon-β therapy

Internal Medicine

Volumn 43, Issue 10, 2004, Pages 931-934

  Konishi, Ichiro ^a   Horiike, Norio ^a   Michitaka, Kojiro ^a   Ochi, Nobuko ^a   Furukawa, Shinya ^a   Minami, Hisaka ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic hepatitis C; IFN ; Renal transplant recipient; Sustained viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BETA INTERFERON; IRON SALT; MEPREDNISONE; TACROLIMUS; VIRUS RNA;

ADULT; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; CHRONIC HEPATITIS; CLINICAL FEATURE; ENDOMETRIOSIS; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; IMMUNOASSAY; IRON DEFICIENCY ANEMIA; JAPAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; LIVING DONOR; METRORRHAGIA; RECIPIENT; SERODIAGNOSIS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; JAPAN; KIDNEY TRANSPLANTATION; RNA, VIRAL; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 8844280842     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.931     Document Type: Article

References (24)

1. Aroldi A, Lampertico P, Elli A, et al. Long-term evolution of anti-HCV-positive renal transplant recipients. Transplant Proc 30: 2076-2078, 1998.
2. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65: 667-670, 1998.
3. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 66: 471-476, 1998.
4. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321: 1501-1506, 1989.
5. Horiike N, Masumoto T, Michitaka K, Kurose K, Akbar SM, Onji M. Response to interferon in chronic hepatitis C due to mixed genotype infection. J Gastroenterol Hepatol 11: 353-357, 1996.
6. Harihara Y, Kurooka Y, Yanagisawa T, et al. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 26: 2075, 1994.
7. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 58: 625-628, 1994.
8. Magnone M, Holley JL, Shapiro R, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 59: 1068-1070, 1995.
9. Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 10: 2104-2106, 1995.
10. Takahara S, Kakimoto K, Kokado Y, et al. Interferon alpha therapy for chronic active hepatitis type C after renal transplantation and allograft rejection. Int Urol Nephrol 27: 479-485, 1995.
11. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74: 512-516, 1996.
12. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 11 (Suppl 1): S135-139, 1998.
13. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 31: 2887-2889, 1999.
14. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 3: 74-78, 2003.
15. Furusyo N, Hayashi J, Ohmiya M, et al. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 44: 608-617, 1999.
16. Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 18: 1319-1325, 1993.
17. Nakao K, Sugiyama H, Makino E, et al. Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. Nephron 90: 498-500, 2002.
18. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22: 1050-1056, 1995.
19. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492, 1998.
20. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493-1499, 1998.
21. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124: 642-650, 2003.
22. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45 1507-1509, 1994.
23. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47: 1412-1418, 1995.
24. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 176: 1614-1617, 1997.